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Introduction 
Cancer is the cause of 1 in 4 deaths in the United States and is the leading cause of 
disease-related death in children. Ewing sarcoma (EWS) is a highly aggressive pediatric and 
adolescent bone tumor that recurs or metastasizes in 50% of pateints.
1-2
 Recurrent and metastatic 
EWS tumors are often lethal because these tumors are highly resistant to the current therapy 
regimen of surgical resection, irradiation, and chemotherapy. Therefore, there is an unmet 
demand for novel therapies that can destroy these aggressive pediatric and adolescent tumors. 
Oncolytic viruses (OVs), such as the rRp450 herpes simplex virus, are promising 
anticancer therapeutics designed to selectively replicate in cancer cells.
3-6,11-12
 The rRp450 virus 
is attenuated to selectively replicate in tumor cells through the depletion of the UL39 virus gene 
encoding  the large subunit of infected cell protein 6 (ICP6) of viral ribonucleotide reductase 
(Fig. 1A). This disruption of ribonucleotide reductase prevents the rRp450 from producing the 
dNTP DNA subunits required for virus replication in healthy cells. However, highly proliferative 
cancer cells produce their own stock of dNTP DNA subunits during DNA replication that 
rRp450 is able to utilize in virus replication. The rRp450 virus also has the insertion of rat gene 
CYP2B1 encoding rat cytochrome P450 enzyme to cleave cyclophosphamide into its active 
form, but this feature was not tested farther in this study. 
While OV anti-tumor efficacy is partially caused by direct infection and lysis of cancer 
cells, stimulation of an anti-cancer immune response also contributes to virus-mediated efficacy.
7
 
Previously we have characterized the response of two highly aggressive human EWS xenograft 
tumors to rRp450 oncolytic herpes simplex virus (oHSV) and found that the A673 cell line is 
vulnerable to rRp450 in vitro and virus replication increases over time in both the in vitro A673 
cell lines and in vivo A673 xenograft tumors (Fig. 1B). The 5838 cell line, however, is highly 
resistant to rRp450 oncolysis in vitro and virus replication diminishes over time in both the in 
vitro 5838 cell lines and in vivo 5838 xenograft tumors. However, we observe a disconnect 
between the in vitro rRp450 cytotoxicity and virus replication to the in vivo anti-tumor response; 
the majority of 5838 tumors respond completely after rRp450 infection while A673 tumors only 
experience a slight inhibition in tumor progression after virus infection. These disconnect 
between in vitro and in vivo response to oncolytiv virus therapy suggests that oncolytic virus 
anti-tumor efficacy in these EWS xenograft tumors is highly dependent on the influence of the 
tumor microenvironment. 
Immunologic responses to infections are known to be modulated by macrophages 
through various cytokines and chemokines and it is now appreciated that the majority of tumors 
are replete with tumor associated macrophages (TAMs).
8-10
 Macrophages are generally activated 
between two polarized activation states: classically activated M1 and alternatively activated M2 
macrophages. M1 classically activated macrophages are considered to be anti-tumor 
macrophages due to their secretion of cytotoxic reactive oxygen species and pro-inflammatory 
cytokines. M2 alternatively activated macrophages are considered to be pro-tumor macrophages 
due to their expression of growth factors and pro-tumor immunosuppressive cytokines, such as 
IL-10 and TGF-β.13-15  
It has been well established that both adult and pediatric tumors are considerably more 
aggressive when there is higher infiltration of M2 tumor macrophages. There are a considerable 
number of studies demonstrating that immunosuppressive M2 TAMs inhibit the anti-tumor 
efficacy of a variety of immunotherapies.
24-26
 However, there are no investigations looking into 
the effect of TAMs on pediatric tumor response to immunotherapy despite the similarities 
between adult and pediatric tumor macrophages.
21-23
 Considering how the tumor macrophages 
are the predominant myeloid cell population in these Ewing sarcoma models, we hypothesize 
that TAMs reduce therapeutic efficacy by producing an immunosuppressive tumor 
microenvironment via IL-10 and TGF-β signaling. 
Methodology 
Human Ewing sarcoma cell lines were cultured in RPMI media supplemented in 10% fetal 
bovine serum and 1% penicillin/streptomycin (Sigma-Aldrich). Tumorigenesis was determined 
with treatment of athymic nude (nu/nu) with 400 ug macrophage depleting clodrosome 
(liposomal clodronate, Encapsula) or control liposome intravenously (Day -3) and 
intraperitoneally (Days -2, -1) prior to right flank subcutaneous implantation of EWS cell lines 
(3.5e6 cells in 100ul 33% matrigel per mouse). Tumor response to oncolytic herpes simplex 
virus was determined with human Ewing sarcoma xenografts implanted into athymic nude mice 
and macrophages were depleted using liposomal clodronate prior to intratumoral injection of 
rRp450 oncolytic HSV (e7 pfu in 100 ul PBS) or control PBS (Days 0, 2). Tumors were allowed 
to grow (50-150 mm
3
) prior to treatment for tumor progression and survival measurement; tumor 
volume was calculated (V=(L)x(W
2)
x(pi/6)) with survival endpoint at tumor volume >2000 mm
3
. 
In vitro and in vivo virus replication was determined through plaque assay of 100 ul serially 
diluted, rRp450 infected EWS cell and tumor samples applied to a fully confluent 12 well plate 
of vero cells, incubating in 37⁰C for 3 days in overlay media, and staining with crystal violet 
prior to plaque counting. F4/80
+
 tumor macrophages were positively selected from tumor 
samples through 33%-66% percolli gradient followed by F4/80
+
 magnetic bead separation; 
sample RNA was harvested and reverse transcribed for qPCR analysis of tumor inflammatory 
signaling and M1/M2 macrophage gene profiles. TGF-β cytokine superfamily receptor signaling 
was inhibited with 150 ug A83-01 (Sigma-Aldrich) small molecule treatment given 
intraperitoneally thrice weekly prior to intratumoral injection of rRp450. 
 
Results 
Tumor associated macrophages are the predominant leukocyte population in a majority of 
aggressive pediatric sarcomas. To determine if macrophages play a role in tumor progression and 
tumorigenesis in Ewing sarcoma xenograft models we depleted the macrophages in athymic 
nude mice using liposomal clodronate (clodrosome, Encapsula) prior to subcutaneous EWS cell 
line implantation. Macrophage depletion significantly inhibited tumorigenesis (Fig. 2A) after 
implantation of A673 into athymic nude mice. These results suggest that the oncolytic HSV-
resistant A673 xenograft tumorigenesis is partially dependent on macrophages. Tumorigenesis in 
the oHSV-sensitive 5838 xenograft was not altered by macrophage depletion (Fig. 2B).  
To determine if macrophages play a role in oncolytic herpes simplex virus resistance in 
EWS xenograft models we allowed the xenograft tumors to grow to a treatable tumor size prior 
to macrophage depletion with clodrosome, followed by rRp450 treatment. When A673 xenograft 
tumors were permitted to grow to 50-150 mm
3
 in volume clodrosome treatment did not 
significantly inhibit tumor progression, but tumor response to rRp450 oncolytic herpes simplex 
virus improved dramatically (Fig. 3A). No change in virus titer was observed in the macrophage 
depleted tumors, suggesting that the improved anti-tumor efficacy of rRp450 in clodrosome 
treated A673 xenografts is not due to improved direct oncolysis of the tumor cells but due to 
other changes in the tumor microenvironment. Clodrosome treatment did not inhibit anti-tumor 
efficacy of rRp450 for the oHSV-sensitive 5838 Ewings sarcoma xenograft tumors (Fig. 3B).  
Macrophages are generally activated either towards a M1 anti-tumor macrophage or a M2 
pro-tumor macrophage polarization state; to determine if the differential anti-tumor response of 
rRp450 treatment between A673 and 5838 Ewing sarcoma tumors following macrophage 
depletion was due to a difference in the tumor macrophage activation state we extracted the 
tumor macrophages from our EWS xenograft models and compared the gene expression profiles 
of macrophages from our oHSV-sensitive 5838 and oHSV-resistant A673 xenografts. The tumor 
macrophages from the oncolytic virus-resistant A673 xenografts displayed a higher expression of 
pro-tumor M2 macrophage associated genes compared to the macrophages from the OV-
sensitive 5838 xenograft tumors following rRp450 infection (Fig. 4). Likewise, the macrophages 
from the OV-sensitive 5838 tumors had higher expression of anti-tumor M1 macrophage 
associated genes compared to the macrophages from the OV-resistant A673 tumors following 
rRp450 infection. Tumor macrophages from A673 xenografts have also demonstrated higher 
expression of immunosuppressive IL-10 and TGF-β cytokines than 5838 tumor associated 
macrophages. Therefore, enhanced OV anti-tumor efficacy in macrophage depleted A673 tumors 
is predicted to be caused by a decrease of anti-inflammatory signals in the tumor 
microenvironment such as IL-10 and TGF-β.18  
TGF-β is known to stimulate macrophages to a pro-tumor M2 activation state and 
dampen the anti-tumor immune response; to determine the role of TGF-β in Ewings sarcoma 
resistance to oncolytic virus therapy we inhibited TGF-β signaling with A-83-01 small inhibitor 
molecule for TGF-β cytokine super family receptor prior to rRp450 treatment. A-83-01 (Sigma-
Aldrich) inhibition of TGF-β signaling in OV-resistant A673 xenograft tumors resulted in a 
modest inhibition of tumor progression and improved response to rRp450 treatment (Fig. 5). It is 
unclear if TGF-β signal inhibition alone is sufficient to sensitize OV-resistant Ewing sarcoma 
tumors to oncolytic virus therapy. It is more likely that depletion of M2 tumor macrophages 
decreases the signaling of a variety of growth factors and immunosuppressive cytokines that 
contribute to Ewings sarcoma resistance to oncolytic herpes simplex virus therapy. 
Conclusions  
Macrophages play a significant role in mitigating OV anti-tumor efficacy. Specifically, 
Ewings sarcoma tumors that promote M2 macrophage polarization are significantly more 
resistant to oncolytic virus therapy, in part due to TGF-β signaling. However, it is likely that the 
combination of a variety of growth factors and immunosuppressive molecules secreted by M2 
macrophages are involved in Ewings sarcoma resistant to oncolytic virus therapy (Fig. 6). There 
is also evidence that pro-angiogenic signaling of M2 macrophages hinder the spread of oncolytic 
viruses throughout the tumor microenvironment.
16-17
 Therefore, macrophage depletion may also 
improve the spread of oncolytic virus in the A673 tumor model.
 
By depleting the macrophages 
with clodrosome, the A673 tumor-bearing mice are deprived of M2 macrophage secreted growth 
factors and immunosuppressive cytokines that normally dampen the anti-tumor immune response 
induced by oncolytic virus infection. These data suggest that the combination of oncolytic virus 
therapy with a macrophage modulatory therapy will improve OV anti-tumor efficacy in patients 
with highly immune suppressive Ewings sarcoma tumors more effectively than combining 
oncolytic viruses with a small molecule inhibitor for a single redundant immunosuppressive 
molecule. Farther study is necessary to determine the exact tumor microenvironment changes 
induced by M2 TAMs that contribute to tumor resistance against OV therapy. There is also the 
chance to identify a potential M2 macrophage activity biomarker to identify Ewings sarcoma 
patients that would benefit from a combination therapy of oncolytic herpes simplex virus and 
macrophage modulation therapy.
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